Latest Market News

FMR Resources has extended its latest diamond drillhole at the Llahuin Project’s Target C, intersecting visual copper and molybdenum mineralisation linked to a key geophysical anomaly. This marks a promising step towards pinpointing the core of a significant porphyry copper-gold-molybdenum system.

Nimy Resources reveals a significant extension to its Block 3 gallium deposit in Western Australia, with a high-resolution magnetic survey indicating a 3.5km strike beyond the current resource boundary. The company is also advancing metallurgical test work and seeking federal funding to support development.

Barton Gold Holdings has kicked off its 2026 drilling campaign at the Tunkillia Gold Project, aiming to secure Ore Reserves, complete a pre-feasibility study, and lodge a Mining Lease application by the end of the year.

Sparc Technologies and the Australian Institute for Machine Learning are developing AI-driven software to transform protective coatings corrosion assessment, promising faster, more accurate results for a global market of testing labs.

Xpedra Resources has appointed mining veteran Scott Funston as Managing Director, aligning leadership with the launch of its maiden drilling program at the promising Springfield Gold Deposit in NSW.

Imricor Medical Systems has welcomed Oklahoma Heart Institute as the fourth U.S. site in its pivotal VISABL-AFL clinical trial, accelerating patient recruitment and the FDA approval pathway for its MRI-guided cardiac ablation technology.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Catalina Resources has verified a copper-rich Volcanogenic Massive Sulphide system at its Breakaway Dam Project in Western Australia, prompting a substantial follow-up drilling program. Concurrently, gold mineralisation continuity is confirmed at the Leghorn Prospect within the Evanston Project.

Aroa Biosurgery’s latest business update reveals promising clinical outcomes from its Myriad trauma study and evolving reimbursement policies that could reshape its market position. The company also projects solid revenue growth for FY26, supported by strategic commercial initiatives.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

Aroa Biosurgery reaffirms strong FY26 guidance, buoyed by favourable US Medicare reimbursement for Symphony and promising trauma study results for Myriad.

Resolution Minerals has taken a significant step towards expanding its footprint in the US capital markets by lodging a registration statement with the SEC and launching an ADR facility, while divesting a non-core Alaskan asset to focus on key US projects.